Please use this identifier to cite or link to this item:
https://doi.org/10.1128/AAC.02145-15
| Title: | Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis | Authors: | Maiga, M.C Ahidjo, B.A Maiga, M Bishai, W.R |
Keywords: | gamma interferon interleukin 1beta isoniazid roflumilast tumor necrosis factor alpha aminopyridine derivative benzamide derivative cyclopropane derivative gamma interferon interleukin 1beta isoniazid phosphodiesterase IV inhibitor roflumilast tuberculostatic agent tumor necrosis factor animal model antibacterial activity Article bacterial clearance chronic obstructive lung disease controlled study cytokine production female food and drug administration median survival time mortality mouse nonhuman priority journal tissue distribution treatment outcome tuberculosis animal Bagg albino mouse biosynthesis disease model drug effects growth, development and aging immunology lung microbiology Mycobacterium tuberculosis survival analysis Tuberculosis, Pulmonary Aminopyridines Animals Antitubercular Agents Benzamides Cyclopropanes Disease Models, Animal Female Interferon-gamma Interleukin-1beta Isoniazid Lung Mice Mice, Inbred BALB C Mycobacterium tuberculosis Phosphodiesterase 4 Inhibitors Survival Analysis Tuberculosis, Pulmonary Tumor Necrosis Factor-alpha |
Issue Date: | 2015 | Publisher: | American Society for Microbiology | Citation: | Maiga, M.C, Ahidjo, B.A, Maiga, M, Bishai, W.R (2015). Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy 59 (12) : 7888-7890. ScholarBank@NUS Repository. https://doi.org/10.1128/AAC.02145-15 | Rights: | Attribution 4.0 International | Abstract: | With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT). © 2015, American Society for Microbiology. All Rights Reserved. | Source Title: | Antimicrobial Agents and Chemotherapy | URI: | https://scholarbank.nus.edu.sg/handle/10635/179634 | ISSN: | 0066-4804 | DOI: | 10.1128/AAC.02145-15 | Rights: | Attribution 4.0 International |
| Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| 10_1128_AAC_02145-15.pdf | 424.86 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License
